194 articles – 65 Notices  [english version]
Fiche concise
Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study.
Ritte R., Lukanova A., Berrino F., Dossus L., Tjønneland A., Olsen A., Overvad T. Filskov, Overvad K., Clavel-Chapelon F., Fournier A. et al
Breast Cancer Research 14, 3 (2012) R76 - http://www.hal.inserm.fr/inserm-00704067
 (22583394) 
Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study.
Rebecca Ritte1, Annekatrin Lukanova1, Franco Berrino2, Laure Dossus1, Anne Tjønneland3, Anja Olsen3, Thure Overvad4, Kim Overvad5, Françoise Clavel-Chapelon6, Agnès Fournier6, Guy Fagherazzi6, Sabine Rohrmann1, 7, Birgit Teucher1, Heiner Boeing8, Krasimira Aleksandrova8, Antonia Trichopoulou9, 10, Pagona Lagiou9, Dimitrios Trichopoulos11, 12, Domenico Palli13, Sabina Sieri14, Salvatore Panico15, Rosario Tumino16, Paolo Vineis17, 18, José Quirós19, Genevieve Buckland20, Maria-José Sánchez21, 22, Pilar Amiano22, 23, María-Dolores Chirlaque22, 24, Eva Ardanaz22, 25, Malin Sund26, Per Lenner27, Bas Bueno-de-Mesquita28, 29, Carla van Gils30, Petra Peeters30, 31, Sanda Krum-Hansen32, Inger Gram32, Eiliv Lund32, Kay-Tee Khaw33, Nick Wareham34, Naomi Allen35, Timothy Key35, Isabelle Romieu36, Sabina Rinaldi36, Afshan Siddiq31, 37, David Cox31, Elio Riboli17, Rudolf Kaaks () 1
1 :  Division of Cancer Epidemiology
German Cancer Research Center (DKFZ)
Im Neuenheimer Feld TP4, Heidelberg, 69120
Allemagne
2 :  Department of Preventive and Predictive Medicine
Fondazione IRCCS Instituto Nazionale dei Tumori
Via Venezian 1, Milan, 20133
Italie
3 :  Institute of Cancer Epidemiology
Danish Cancer Society
Danemark
4 :  Department of Cardiology
Aalborg Hospital – Aarhus University
Hobrovej 18-22, Aalborg, 9100
Danemark
5 :  Department of Epidemiology
School of public health – Aarhus University
Bartholins Allé 2, Aarhus, 8000
Danemark
6 :  CESP - Centre de recherche en épidémiologie et santé des populations
INSERM : U1018 – Université Paris XI - Paris Sud – Hôpital Paul Brousse – Assistance publique - Hôpitaux de Paris (AP-HP)
16 avenue Paul Vaillant Couturier 94807 Villejuif Cedex, France
France
7 :  Division of Cancer Epidemiology and Prevention
Institute of Social and Preventive Medicine
Hirschengraben 84, Zurich, CH-8001
Suisse
8 :  Department of Epidemiology
German Institute of Human Nutrition
Potsdam-Rehbruecke, Arthur-Scheunert-Allee 114-116, Nuthetal, 14558
Allemagne
9 :  WHO Collaborating Center for Food and Nutrition Policies
Department of Hygiene – Epidemiology and Medical Statistics – University of Athens – Athens Medical School
Asias Street 75 M., Goudi, Athens, GR-115 27
Grèce
10 :  Hellenic Health Foundation
University of Athens
Tetrapoleos Street 10-12, Athens, GR-115 27
Grèce
11 :  Department of Epidemiology
Harvard School of Public Health
Huntington Avenue 677, Boston, MA 02115
États-Unis
12 :  Bureau of Epidemiologic Research
Academy of Athens
Panepistimiou Street 28, Athens, GR-106 79
Grèce
13 :  Molecular and Nutritional Epidemiology Unit
Cancer Research and Prevention Institute (ISPO) – Scientific Institute of Tuscany
Via Cosimo il Vecchio 2, Florence, 50139
Italie
14 :  Nutritional Epidemiology Unit
Fondazione IRCCS Istituto Nazionale dei Tumori
Via Venezian1, Milano, 20133
Italie
15 :  Department of Clinical and Experimental Medicine
Medical School – Federico II University
Via S. Pansini 5 Naples, 80131
Italie
16 :  Cancer Registry and Histopathology Unit
'Civile M.P. Arezzo' Hospital ASP 7
Via Dante 109, Ragusa, 97100
Italie
17 :  Centre for Environment and Health
Imperial College London – School of public health
South Kensington Campus, London SW7 2AZ
Royaume-Uni
18 :  HuGeF - Human Genetics Foundation
University of Torino
Via Nizza 52, Torino,10126
Italie
19 :  Public Health and Health Planning Directorate
Universidad de Oviedo
C/Ciriaco Miguel Virgil 9, Asturias, CP 33006
Espagne
20 :  Unit of Nutrition, Environment and Cancer
Catalan Institute of Oncology (ICO-IDIBELL) – Cancer Epidemiology Research Programme
Avda Gran Via 199-203, Barcelona, 08907
Espagne
21 :  Granada Cancer Registry
Andalusian School of Public Health
4. Campus Universitario de la Cartuja 18080 Granada
Espagne
22 :  CIBERESP - Consorcio de Investigación Biomédica en Red especializado en Epidemiología y Salud Pública
Los Centros de Investigación Biomédica en Red (CIBER)
C/Melchor Fernández Almagro 3-5, Madrid, 28029
Espagne
23 :  Public Health Division of Gipuzkoa
Institute BIO Donostia – Health Department
Basque Region, Avda de Navarra 4, Gipuzkoa, 20013
Espagne
24 :  Department of Epidemiology
Murcia Regional Health Authority
Ronda de Levante 11, Murcia, 30008
Espagne
25 :  Navarra Public Health Institute
Leyre 15
Navarra Public Health Institute, Leyre 15, Pamplona, 31003, Spain
Espagne
26 :  Department of Surgery and Perioperative Sciences
Umea University Hospital
Building 10:1 Umeå, SE-901 85
Suède
27 :  Department of Oncology and Radiation Sciences, Oncology
Umea University Hospital
Building 6M, Umeå, SE-901 87
Suède
28 :  National Institute for Public Health and the Environment
National Institute
Antonie van Leeuwenhoeklaan 9, Bilthoven, 3721 MA
Pays-Bas
29 :  Department of Gastroenterology and Hepatology
University Medical Centre
Heidelberglaan 100, Utrecht, 3584 CX
Pays-Bas
30 :  Julius Center for Health Sciences and Primary Care
University Medical Center
Heidelberglaan 100, Utrecht, 3508 GA
Pays-Bas
31 :  Department of Epidemiology and Biostatistics
School of public health – Faculty of Medicine – Imperial College London
South Kensington Campus, London SW7 2AZ
Royaume-Uni
32 :  Institute of Community Medicine
University of Tromsø
Norvège
33 :  School of Clinical Medicine
University of Cambridge
The Old Schools, Trinity Lane, CB2 1TN
Royaume-Uni
34 :  Medical Research Council
Epidemiology Unit – Addenbrooke's Hospital
Hills Road, Cambridge, CB2 0QQ
Royaume-Uni
35 :  Cancer Epidemiology Unit
University of Oxford
Royaume-Uni
36 :  Unité d'épidémiologie nutritionnelle
Section Nutrition et Métabolisme – Centre Internationale de la recherche sur le cancer (CIRC)
150 Cours Albert Thomas, Lyon, 69372
France
37 :  Department of Genomics of Common Disease
School of public health – Imperial College London
South Kensington Campus, London SW7 2AZ
Royaume-Uni
ABSTRACT: INTRODUCTION: Associations of hormone-receptor positive breast cancer with excess adiposity are reasonably well characterized; however, uncertainty remains regarding the association of body mass index (BMI) with hormone-receptor negative malignancies, and possible interactions by hormone replacement therapy (HRT) use. METHODS: Within the European EPIC cohort, Cox proportional hazards models were used to describe the relationship of BMI, waist and hip circumferences with risk of estrogen receptor (ER)-progesterone receptor (PR)- (n=1,021) and ER+PR+ (n=3,586) breast tumors within five-year age bands. Among postmenopausal women, the joint effects of BMI and HRT use were analyzed. RESULTS: For risk of ER-PR- tumors, there was no association of BMI across the age bands. However, when analyses were restricted to postmenopausal HRT never users, a positive risk association with BMI (3rd versus 1st tertile HR=1.47[1.01-2.15]) was observed. BMI was inversely associated with ER+PR+ tumors among women aged [less than or equal to]49 years (per 5kg/m2 increase, HR=0.79[95%CI 0.68-0.91]), and positively associated with risk among women [greater than or equal to]65 years (HR=1.25[1.16-1.34]). Adjusting for BMI, waist and hip circumferences showed no further associations with risks of breast cancer subtypes. Current use of HRT was significantly associated with an increased risk of receptor-negative (HRT current use compared to HRT never use HR: 1.30[1.05-1.62]) and positive tumors (HR: 1.74[1.56-1.95]), although this risk increase was weaker for ER-PR- disease (Phet=0.035). The association of HRT was significantly stronger in the leaner women (BMI [less than or equal to]22.5kg/m2) than for more overweight women (BMI [greater than or equal to]25.9kg/m2) for, both, ER-PR- (HR: 1.74[1.15-2.63]) and ER+PR+ (HR: 2.33[1.84-2.92]) breast cancer and was not restricted to any particular HRT regime. CONCLUSIONS: An elevated BMI may be positively associated with risk of ER-PR- tumors, among postmenopausal women who never used HRT. Furthermore, postmenopausal HRT users were at an increased risk of ER-PR- as well as ER+PR+ tumors, especially among leaner women. For HR-positive tumors, but not for HR-negative tumors, our study confirms an inverse association of risk with BMI among young women of premenopausal age. Our data provide evidence for a possible role of sex hormones in the etiology of HR-negative tumors.
Sciences du Vivant/Cancérologie
Anglais
1465-542X

Articles dans des revues avec comité de lecture
10.1186/bcr3186
Breast Cancer Research (Breast Cancer Res)
Publisher BioMed Central
ISSN 1465-5411 
internationale
14/05/2012
14/05/2012
14
3
R76

This work was (partly) supported by a grant from the German Research Foundation, Graduiertenkolleg 793: Epidemiology of communicable and chronic noncommunicable diseases and their interrelationships. The coordination of EPIC is financially supported by the European Commission Directorate General for Health and Consumer Protection (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by the Danish Cancer Society (Denmark); Ligue contre le Cancer, Mutuelle Générale de l'Education Nationale, and the Institut National de la Santé et de la Recherche Médicale (France); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and the Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation, the Stavros Niarchos Foundation and the Hellenic Ministry of Health and Social Solidarity; the Italian Association for Research on Cancer (AIRC) and the National Research Council (Italy); the Dutch Ministry of Public Health, Welfare and Sport (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), and Statistics Netherlands (The Netherlands); ERC-2009-AdG 232997 and Nordforsk, the Nordic Centre of Excellence programme on Food, Nutrition and Health. (Norway); the Health Research Fund (FIS), Regional Governments of Andalucía, Asturias, Basque Country, Murcia (number 6236) and Navarra, and ISCIII RTICC Red Temática de Investigación Cooperativa en Cáncer (R06/0020) (Spain); the Swedish Cancer Society, Swedish Scientific Council and the Regional Government of Skåne and Västerbotten (Sweden); Cancer Research UK, and the Medical Research Council, (United Kingdom).
Liste des fichiers attachés à ce document : 
PDF
bcr3186.pdf(305.9 KB)
ANNEX
bcr3186.xml(204.2 KB)
BCR3186-S2.PPT(157 KB)
BCR3186-S8.XLS(28 KB)
BCR3186-S5.PPT(156 KB)
BCR3186-S11.PPT(143.5 KB)
BCR3186-S6.XLS(27.5 KB)
BCR3186-S4.PPT(155 KB)
BCR3186-S3.PPT(156 KB)
BCR3186-S10.PPT(150.5 KB)
BCR3186-S7.XLS(29.5 KB)
BCR3186-S9.XLS(28 KB)
BCR3186-S1.XLS(23 KB)